Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program

Christopher L. Morton, John M. Maris, Stephen T. Keir, Richard Gorlick, E. Anders Kolb, Catherine A. Billups, Jianrong Wu, Malcolm A. Smith, Peter J. Houghton

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Cediranib (AZD2171) is a potent small molecule inhibitor of vascular endothelial growth factor (VEGF) receptors. Cediranib has demonstrated single agent activity in several adult cancers and is being studied in combination with standard cytotoxic agents in multiple disease settings. Procedures: Cediranib was tested in vivo against six childhood tumor xenograft models (four sarcomas, one glioblastoma, one neuroblastoma) alone or combined with cyclophosphamide (two models), vincristine (three models) or cisplatin (one model), each administered at its maximum tolerated dose, or rapamycin (six models). Results: The combination of cediranib with standard cytotoxic agents was superior to the cytotoxic agent used alone for a single xenograft (one of the three xenografts evaluated for the vincristine-cediranib combination). The cediranib-cyclophosphamide combination was inferior to single agent cyclophosphamide in time to event for both models studied and was significantly inferior for one of the models. Cediranib combined with rapamycin was superior to each of the agents used alone in two of the six models and was determined to be additive or supra-additive with rapamycin in four models, although the effects were not large. Conclusions: Cediranib combined with cytotoxic chemotherapy agents demonstrated little or no benefit (and in one case was significantly inferior) compared to chemotherapy alone for the six pediatric cancer xenografts studied. By contrast, the combination of cediranib with rapamycin was additive or supra-additive in four of the six models in terms of prolongation of time to event, though tumor regressions were not observed for this combination.

Original languageEnglish (US)
Pages (from-to)566-571
Number of pages6
JournalPediatric Blood and Cancer
Volume58
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Pediatrics
Cytotoxins
Sirolimus
Neoplasms
Heterografts
Cyclophosphamide
Vincristine
cediranib
Drug Therapy
Vascular Endothelial Growth Factor Receptor
Maximum Tolerated Dose
Glioblastoma
Neuroblastoma
Sarcoma
Cisplatin

Keywords

  • AZD2171
  • Cediranib
  • Developmental therapeutics
  • Preclinical testing

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Morton, C. L., Maris, J. M., Keir, S. T., Gorlick, R., Kolb, E. A., Billups, C. A., ... Houghton, P. J. (2012). Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatric Blood and Cancer, 58(4), 566-571. https://doi.org/10.1002/pbc.23159

Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. / Morton, Christopher L.; Maris, John M.; Keir, Stephen T.; Gorlick, Richard; Kolb, E. Anders; Billups, Catherine A.; Wu, Jianrong; Smith, Malcolm A.; Houghton, Peter J.

In: Pediatric Blood and Cancer, Vol. 58, No. 4, 04.2012, p. 566-571.

Research output: Contribution to journalArticle

Morton, CL, Maris, JM, Keir, ST, Gorlick, R, Kolb, EA, Billups, CA, Wu, J, Smith, MA & Houghton, PJ 2012, 'Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 58, no. 4, pp. 566-571. https://doi.org/10.1002/pbc.23159
Morton, Christopher L. ; Maris, John M. ; Keir, Stephen T. ; Gorlick, Richard ; Kolb, E. Anders ; Billups, Catherine A. ; Wu, Jianrong ; Smith, Malcolm A. ; Houghton, Peter J. / Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. In: Pediatric Blood and Cancer. 2012 ; Vol. 58, No. 4. pp. 566-571.
@article{068ac96e48344c309ad7b35b2b536ece,
title = "Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program",
abstract = "Background: Cediranib (AZD2171) is a potent small molecule inhibitor of vascular endothelial growth factor (VEGF) receptors. Cediranib has demonstrated single agent activity in several adult cancers and is being studied in combination with standard cytotoxic agents in multiple disease settings. Procedures: Cediranib was tested in vivo against six childhood tumor xenograft models (four sarcomas, one glioblastoma, one neuroblastoma) alone or combined with cyclophosphamide (two models), vincristine (three models) or cisplatin (one model), each administered at its maximum tolerated dose, or rapamycin (six models). Results: The combination of cediranib with standard cytotoxic agents was superior to the cytotoxic agent used alone for a single xenograft (one of the three xenografts evaluated for the vincristine-cediranib combination). The cediranib-cyclophosphamide combination was inferior to single agent cyclophosphamide in time to event for both models studied and was significantly inferior for one of the models. Cediranib combined with rapamycin was superior to each of the agents used alone in two of the six models and was determined to be additive or supra-additive with rapamycin in four models, although the effects were not large. Conclusions: Cediranib combined with cytotoxic chemotherapy agents demonstrated little or no benefit (and in one case was significantly inferior) compared to chemotherapy alone for the six pediatric cancer xenografts studied. By contrast, the combination of cediranib with rapamycin was additive or supra-additive in four of the six models in terms of prolongation of time to event, though tumor regressions were not observed for this combination.",
keywords = "AZD2171, Cediranib, Developmental therapeutics, Preclinical testing",
author = "Morton, {Christopher L.} and Maris, {John M.} and Keir, {Stephen T.} and Richard Gorlick and Kolb, {E. Anders} and Billups, {Catherine A.} and Jianrong Wu and Smith, {Malcolm A.} and Houghton, {Peter J.}",
year = "2012",
month = "4",
doi = "10.1002/pbc.23159",
language = "English (US)",
volume = "58",
pages = "566--571",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program

AU - Morton, Christopher L.

AU - Maris, John M.

AU - Keir, Stephen T.

AU - Gorlick, Richard

AU - Kolb, E. Anders

AU - Billups, Catherine A.

AU - Wu, Jianrong

AU - Smith, Malcolm A.

AU - Houghton, Peter J.

PY - 2012/4

Y1 - 2012/4

N2 - Background: Cediranib (AZD2171) is a potent small molecule inhibitor of vascular endothelial growth factor (VEGF) receptors. Cediranib has demonstrated single agent activity in several adult cancers and is being studied in combination with standard cytotoxic agents in multiple disease settings. Procedures: Cediranib was tested in vivo against six childhood tumor xenograft models (four sarcomas, one glioblastoma, one neuroblastoma) alone or combined with cyclophosphamide (two models), vincristine (three models) or cisplatin (one model), each administered at its maximum tolerated dose, or rapamycin (six models). Results: The combination of cediranib with standard cytotoxic agents was superior to the cytotoxic agent used alone for a single xenograft (one of the three xenografts evaluated for the vincristine-cediranib combination). The cediranib-cyclophosphamide combination was inferior to single agent cyclophosphamide in time to event for both models studied and was significantly inferior for one of the models. Cediranib combined with rapamycin was superior to each of the agents used alone in two of the six models and was determined to be additive or supra-additive with rapamycin in four models, although the effects were not large. Conclusions: Cediranib combined with cytotoxic chemotherapy agents demonstrated little or no benefit (and in one case was significantly inferior) compared to chemotherapy alone for the six pediatric cancer xenografts studied. By contrast, the combination of cediranib with rapamycin was additive or supra-additive in four of the six models in terms of prolongation of time to event, though tumor regressions were not observed for this combination.

AB - Background: Cediranib (AZD2171) is a potent small molecule inhibitor of vascular endothelial growth factor (VEGF) receptors. Cediranib has demonstrated single agent activity in several adult cancers and is being studied in combination with standard cytotoxic agents in multiple disease settings. Procedures: Cediranib was tested in vivo against six childhood tumor xenograft models (four sarcomas, one glioblastoma, one neuroblastoma) alone or combined with cyclophosphamide (two models), vincristine (three models) or cisplatin (one model), each administered at its maximum tolerated dose, or rapamycin (six models). Results: The combination of cediranib with standard cytotoxic agents was superior to the cytotoxic agent used alone for a single xenograft (one of the three xenografts evaluated for the vincristine-cediranib combination). The cediranib-cyclophosphamide combination was inferior to single agent cyclophosphamide in time to event for both models studied and was significantly inferior for one of the models. Cediranib combined with rapamycin was superior to each of the agents used alone in two of the six models and was determined to be additive or supra-additive with rapamycin in four models, although the effects were not large. Conclusions: Cediranib combined with cytotoxic chemotherapy agents demonstrated little or no benefit (and in one case was significantly inferior) compared to chemotherapy alone for the six pediatric cancer xenografts studied. By contrast, the combination of cediranib with rapamycin was additive or supra-additive in four of the six models in terms of prolongation of time to event, though tumor regressions were not observed for this combination.

KW - AZD2171

KW - Cediranib

KW - Developmental therapeutics

KW - Preclinical testing

UR - http://www.scopus.com/inward/record.url?scp=84863116086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863116086&partnerID=8YFLogxK

U2 - 10.1002/pbc.23159

DO - 10.1002/pbc.23159

M3 - Article

C2 - 21538824

AN - SCOPUS:84863116086

VL - 58

SP - 566

EP - 571

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -